MGMT and central nervous system cancer: Some known mechanisms contribute to the resistance to treatment that these tumours present, such as the preferential activation of DNA-damage response pathways in glioma stem cells in response to radiotherapy and the inhibition of apoptosis, upregulation of multidrug resistance genes and the genomic rearrangement of MGMT contribute to the resistance to standard chemotherapy with temozolomide [1].